A Practical Framework for Evaluating Peptide Quality

The peptide therapy market is growing fast, and with that growth comes a flood of suppliers making bold claims about purity, potency, and compliance. For clinics evaluating new manufacturing partners, a Certificate of Analysis alone isn't enough. You need a repeatable framework that separates credible producers from the noise.

Here's how we approach it at WestReach Bio — and how your team can apply the same thinking.

Start with the Lab, Not the Product

Before evaluating any individual peptide, look at the facility producing it. Key questions: Is the manufacturer operating under current Good Manufacturing Practice (cGMP) guidelines? Do they hold ISO/IEC 17025 accreditation for their testing labs? Can they produce batch records on demand?

A manufacturer who can't answer these questions clearly is a red flag, regardless of how competitive their pricing is. cGMP compliance isn't optional — it's the baseline that protects your patients and your practice.

Dig Into Analytical Methods

COAs are only as good as the methods behind them. Ask for method validation data — specificity, linearity, accuracy, precision, and robustness. HPLC purity percentages mean nothing if the method hasn't been validated for the specific peptide sequence you're sourcing.

Third-party confirmatory testing adds another layer. We recommend sending samples to an independent lab for identity confirmation (mass spectrometry) and purity verification before any clinical deployment. The cost is minimal compared to the liability of distributing a substandard product.

Map the Cold Chain End to End

Peptides are sensitive molecules. Degradation from temperature excursions during shipping can compromise efficacy without any visible change to the product. Your quality framework should include temperature monitoring requirements for every shipment, defined acceptable ranges with documented excursion protocols, and storage specifications at the clinic level.

We run pilot shipments with active data loggers before scaling any new supply relationship. It's a simple step that catches problems before patients are affected.

Documentation Readiness

Regulatory scrutiny on peptide therapies is increasing. Your documentation package for each product should include complete batch records with lot traceability, stability data (ideally 12+ months under ICH guidelines), certificates of analysis with method references, material safety data sheets, and adverse event reporting procedures.

If a manufacturer can't provide this package within a reasonable timeframe, they're not ready for clinical-grade distribution.

Build Review Cadence Into the Relationship

Quality isn't a one-time check. We schedule quarterly business reviews with every manufacturing partner, covering lot rejection rates and trend analysis, any changes to formulation or process, updated stability data, and regulatory landscape changes.

This ongoing dialogue catches drift before it becomes a problem and builds the kind of trust that sustains long-term partnerships.

The bottom line: peptide quality evaluation isn't about finding the cheapest supplier with the highest purity number on a COA. It's about building a defensible, documented process that protects your patients, your practitioners, and your practice.